NoBsRx review
Every program is named low-dose, and all three twelve-week blocks cost the same regardless of molecule.
The verdict
NoBsRx publishes $140 a month for injectable semaglutide, $179 for the oral and $140 for injectable tirzepatide. Each program is labeled low-dose. All three twelve-week blocks are $409.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Dose pricing
- Flat across doses
- Injection
- From $179/mo
- Oral
- From $199/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
NoBsRx sells both molecules, injected and oral, as named low-dose programs. Three lines carry a monthly figure. Each also carries a twelve-week price, and those are identical across the three.
Who writes the prescription, and what do they see?
A prescription precedes dispensing. The pages name the program rather than the clinician. What the intake asks is not published. The dose framing is stated, which is the rarer disclosure of the two.
Calling the programs low-dose on the product itself is the notable act. It stops the rate reading as a standard starting dose. NoBsRx states the rate holds at every dose, which on a low-dose program is the claim worth confirming at intake.
What happens when the dose goes up?
The rate is stated to hold. The programs are low-dose by name. A buyer moving to standard dosing is not covered by anything published. The pages do not say whether that move exists.
What the price includes
$140 a month is the injectable figure on both molecules, which removes the usual tirzepatide premium entirely. The oral runs $179. The twelve-week block is $409 whichever program is chosen, so the block is priced by term rather than by molecule. That is an unusual structure and it is published rather than inferred.
What it claims, and what it cites
Every line is compounded. None is FDA-approved. No agency reviews them before dispensing. A low-dose program is a smaller quantity of the same molecule, not a different one.
Where it holds up, and where it does not
- Strength: Every program is labeled low-dose
- Strength: Tirzepatide carries no premium here
- Strength: The twelve-week price is published too
- Limitation: All programs are low-dose only
- Limitation: No milligram figure is published
- Limitation: Standard dosing is not addressed
- Limitation: No state coverage list is recorded
What the evidence says about this kind of treatment
The assessment above is about NoBsRx. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants a low-dose program named as one and priced the same either molecule.
- Wrong for
- A reader who expects to move to a standard dose.
The evidence behind what NoBsRx prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How NoBsRx compares
| Seller | Who it suits | Go |
|---|---|---|
 Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | See Zera Health → |
| Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | See Bayan Health → |
 Good Girl Rx | A reader who will read the one-month rung rather than the headline, and wants microdoses labeled as such | See Good Girl Rx → |
More GLP-1 telehealth sellers reviews: Nu Image MedicalNuBloomNucore HealthNuDay RxNuuVimNuviaRx
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Why does tirzepatide cost the same as semaglutide?
- NoBsRx prices both injectable programs at $140 a month. Most sellers charge a premium for tirzepatide; this one does not.
- What is a low-dose program?
- A smaller quantity of the same molecule. NoBsRx names all three programs that way rather than leaving the rate to read as a standard dose.
- Is twelve weeks cheaper?
- It is $409 on every program. That sits below three months of the oral at its monthly rate, and above three months of either injection.
- Is NoBsRx expensive compared with other GLP-1 telehealth sellers?
- NoBsRx publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NoBsRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.